Literature DB >> 2940999

Abnormal retinal function associated with isotretinoin therapy for acne.

R G Weleber, S T Denman, J M Hanifin, W J Cunningham.   

Abstract

Three of 50 patients treated with isotretinoin (1 mg/kg/day) for cystic acne complained of poor night vision and/or excessive glare sensitivity. While still receiving the drug or shortly thereafter, two patients were found to have abnormal dark-adaptation curves, with elevations of either cone or rod thresholds, or both. Two patients had abnormal electroretinograms (ERGs). One had a mildly abnormal electro-oculogram. The dark-adaptation curves were normal for one patient several months after isotretinoin therapy was discontinued. Two patients had elevated cone thresholds at least one year later. Six months following cessation of therapy, the ERG was still abnormal for one patient, but continued improvement was evident at 25 months; for the second patient, the ERG was normal at one year. Analysis of Naka-Rushton parameters for the ERG scotopic b-wave stimulus-response curves indicated response compression for two patients, as evidenced by a reduction in the maximum response. For one patient, the half-saturation constant was elevated 0.7 log units, suggesting reduction of retinal sensitivity, perhaps from decrease in retinal photopigment concentration. We suspect that isotretinoin may complete for normal retinol binding sites on cell surfaces or transport molecules. A prospective study is currently underway to determine if a clinically measurable adverse effect on retinal function is seen with greater frequency.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940999     DOI: 10.1001/archopht.1986.01050180065031

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  16 in total

1.  Therapy for macular degeneration: insights from acne.

Authors:  Janet R Sparrow
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

Review 2.  Light and inherited retinal degeneration.

Authors:  D M Paskowitz; M M LaVail; J L Duncan
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

3.  Does use of isotretinoin rule out a career in flying?

Authors:  S P Mollan; M Woodcock; R Siddiqi; J Huntbach; P Good; R A H Scott
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

4.  Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration.

Authors:  Roxana A Radu; Nathan L Mata; Steven Nusinowitz; Xinran Liu; Paul A Sieving; Gabriel H Travis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

Review 5.  Key enzymes of the retinoid (visual) cycle in vertebrate retina.

Authors:  Philip D Kiser; Marcin Golczak; Akiko Maeda; Krzysztof Palczewski
Journal:  Biochim Biophys Acta       Date:  2011-04-05

6.  ISCEV extended protocol for the stimulus-response series for the dark-adapted full-field ERG b-wave.

Authors:  Mary A Johnson; Brett G Jeffrey; André M V Messias; Anthony G Robson
Journal:  Doc Ophthalmol       Date:  2019-03-30       Impact factor: 2.379

7.  Experimental carotenoid retinopathy. I. Functional and morphological alterations of the rabbit retina after 11 months dietary carotenoid application.

Authors:  U Weber; W Kern; G E Novotny; G Goerz; S Hanappel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

8.  Learning effect of dark adaptation among normal subjects.

Authors:  John Christoforidis; Xiaoli Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-05-21       Impact factor: 3.117

Review 9.  Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents.

Authors:  Gabriel H Travis; Marcin Golczak; Alexander R Moise; Krzysztof Palczewski
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 10.  Drug-induced ocular disorders.

Authors:  Junping Li; Ramesh C Tripathi; Brenda J Tripathi
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.